Ankit Ajit Desai MD FAHA
Echocardiography, Vascular Medicine, Cardiovascular Disease Genetics
Professor, Medicine, Indiana University, Indianapolis, IN
1801 N Senate Blvd# SutieIndianapolis, IN 46202
Fax+1 317-962-9657
Overview of Dr. Desai
Dr. Ankit Desai is a cardiologist in Indianapolis, IN and is affiliated with Indiana University Health University Hospital. He received his medical degree from University of Illinois College of Medicine and has been in practice 14 years. He also speaks multiple languages, including English, Gujarati, Hindi, and Spanish. He specializes in adult heart disease, pulmonary vascular medicine, sickle cell disease, and cardiovascular genetics and is experienced in pulmonary hypertension, sickle-cell anemia, and medical genetics.
Education & Training
University of ChicagoFellowship, Cardiovascular Disease, 2008 - 2010
Sutter Health/California Pacific Medical CenterResidency, Internal Medicine, 2003 - 2006
University of Illinois College of MedicineClass of 2003
Certifications & Licensure
IN State Medical License 2018 - 2027
AZ State Medical License 2014 - 2020
IL State Medical License 2006 - 2014
CA State Medical License 2003 - 2006
American Board of Internal Medicine Cardiovascular Disease
Publications & Presentations
PubMed
- Blood Pressure Effects and Risk of Hypotension due to Intravenous Furosemide in Acute Decompensated Heart Failure.Nicholas E Harrison, Meghana Bhaskara, Kyle Wilson, Ankit A Desai, Nicholas Montelauro
Academic Emergency Medicine. 2025-08-28 - Cardiomyocyte-restricted MIAT deletion is sufficient to protect against murine myocardial infarction.Taiki Hayasaka, Satoshi Kawaguchi, Marisa N Sepúlveda, Jian-Peng Teoh, Bruno Moukette
Cell Death Discovery. 2025-02-20 - 12 citationsLysosomal dysfunction and inflammatory sterol metabolism in pulmonary arterial hypertension.Lloyd D Harvey, Mona Alotaibi, Yi-Yin Tai, Ying Tang, Hee-Jung J Kim
Science. 2025-01-24
Press Mentions
Early Researchers Engage in Molecular and Technology-Driven Cardiovascular ResearchDecember 4th, 2024- New Insights and Potential Treatments for Pulmonary HypertensionAugust 21st, 2024
- Beta Blocker Used to Treat Heart Problems and Other Medical Concerns Could Be New Treatment for Sickle Cell CardiomyopathyJanuary 5th, 2024
- Join now to see all
Grant Support
- Risk stratification in pulmonary arterial hypertension: Intersection of OMICs and longitudinal phenotypes through the PAH BiobankCINCINNATI CHILDRENS HOSP MED CTR2022–2026
- Sickle cell diseaseNHLBI2017–2022
Professional Memberships
- Fellow
- Fellow
- Member
- Pulmonary Hypertension AssociationScientific Leadership Council Member
- Member
- Pulmonary hypertension breakthrough initiativeMember
Other Languages
- Gujarati, Hindi, Spanish
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
